Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 13/20 | 0.46 |
| ▸ | KDR | P35968 | 13/20 | 0.46 |
| ▸ | LYN | P07948 | 11/20 | 0.46 |
| ▸ | INSR | P06213 | 9/20 | 0.46 |
| ▸ | SRC | P12931 | 9/20 | 0.46 |
| ▸ | HCK | P08631 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588433 | 0.86 | LCK (0.46) | LCKKDRLYNINSRSRC | |
| SCHEMBL3591946 | 0.81 | LMNA (0.49) | NPC1ALDH1A1RAB9ALCKKDR | |
| SCHEMBL3587533 | 0.79 | NPC1 (0.47) | MEN1KMT2AKDM4ENPC1ALDH1A1 | |
| SCHEMBL3589999 | 0.75 | KDR (0.66) | LCKKDRLYNINSRSRC | |
| SCHEMBL9967409 | 0.75 | LCK (0.64) | LCKKDRLYNINSRSRC | |
| SCHEMBL3591291 | 0.73 | BRAF (0.45) | LCKKDRLYNINSRSRC | |
| SCHEMBL5908394 | 0.73 | NPC1 (0.71) | MEN1KMT2AKDM4ENPC1ALDH1A1 | |
| SCHEMBL3587090 | 0.72 | LMNA (0.49) | NPC1ALDH1A1RAB9ALCKKDR | |
| SCHEMBL3591361 | 0.71 | LMNA (0.48) | NPC1ALDH1A1RAB9ASMN1; SMN2BRAF | |
| SCHEMBL27784507 | 0.70 | NPC1 (0.47) | MEN1KMT2AKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | claimed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | MEN1 3985/4885KMT2A 1139/4885KDM4E 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.